Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Eligibility Criteria

• 1. Received ATG or Alemtuzumab within 21 days of viral-specific T cell infusion and a lack of evidence of T cell survival, defined by \<10 CD3+ T cells/uL (in unique situations, plasmapheresis may be considered).
• 2. Active acute GVHD grades II-IV.
• 3. Active severe chronic GVHD.
• 4. Received donor lymphocyte infusion, with the exception of a fraction of an umbilical cord blood, within 21 days of planned viral-specific T cell infusion. Subjects receiving a fraction of an umbilical cord blood within 21 days of the viral-specific T cell infusion will not be excluded.
• 5. Active and uncontrolled relapse of malignancy (other than EBV+ post-transplant lymphoproliferative disorder or lymphoma).
• 6. Anticipated initiation of new lymphotoxic therapy within 4 weeks of viral-specific T cell infusion.
• 7. Patients who are pregnant or lactating.
• 8. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, or concomitant medications, which, in the opinion of the investigator, may pose additional risks to participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.
• 1. Age ≥ 12\*
• 2. Able to understand and sign the consent/assent to the procedure
• 3. Partial (2/6 or more) HLA match to the recipient
• 4. A pediatric donor could be selected as a donor only if a suitable adult donor is not available (as attested by the research team) or is ineligible according to FACT requirements. For pediatric donors:
• * Related to the recipient
• * Apheresis does not need a blood prime before the procedure
• * Adequate peripheral venous access
• * Explicit evaluation of the donors' willingness to donate cells, as attested by the research team
• * Must have understanding that they are helping their ill relative, as attested by the research team
• * Will gain emotional/psychological benefit from their ability to help and want to donate for a relative, as attested by the research team
• * Inclusion of minor donors that are not relatives of the recipient will need to be evaluated on a case-by-case basis for the IRB to evaluate the potential benefit to these participants (whether they will receive an emotional and psychological boost from helping the recipient) \*If the only suitable donor is less than 12 years old, a single patient exception to this inclusion criteria will be submitted and approved by the IRB before obtaining the donor's assent and their LAR consent.
• 1. Donor is pregnant
• 2. Donor is HIV positive
• 3. Donor is positive for hepatitis B and/or hepatitis C
• 4. Deemed to be a high-risk donor based on responses to donor risk questionnaire
• 5. Deemed high risk due to preexisting medical condition or abnormal lab results